SAPHRIDONE Domperidone Maleate 10mg Tablet 1's
RXDRUG-DRP-7345-1pc
- View all variations as list
| CODE | Dosage Strength | Drug Packaging | Availability | Price | ||
|---|---|---|---|---|---|---|
|
RXDRUG-DRP-7345-1pc
|
In stock
|
₱250 |
Discreet Packaging
We recognize that purchasing medications can be a deeply personal matter. To respect your privacy, we ensure that all orders are packaged discreetly, with no indication of the contents on the packaging. This means that even our couriers remain unaware of the package contents.
Furthermore, we uphold strict confidentiality standards. We guarantee that your order information will never be disclosed to any third party. Your trust is paramount to us, and we are committed to safeguarding your privacy at every step of the process. Our dedication to discretion and confidentiality is part of our unwavering commitment to you, our valued customer.
FDA-registered Products
FDA-licensed Pharmacies
Sellers of this product
Features
Brand
Saphridone
Full Details
Dosage Strength
10 mg
Drug Ingredients
- Domperidone
Drug Packaging
Tablet 1's
Generic Name
Domperidone Maleate
Dosage Form
Tablet
Registration Number
DRP-7345
Drug Classification
Prescription Drug (RX)
Description
Indications
Short-term treatment of nausea and vomiting. Relief of symptoms associated with non-ulcer dyspepsia or indigestion. Used along with paracetamol in the symptomatic treatment of migraine.
Dosage
Adult: As short-term treatment: ≥35 kg: 10 mg up to tid. Max: 30 mg daily. Max treatment duration: 1 week. Use the lowest effective dose for the shortest possible duration needed to control the symptoms.
Child: ≥12 years weighing ≥35 kg: Same as adult dose.
Child: ≥12 years weighing ≥35 kg: Same as adult dose.
Administration
Should be taken on an empty stomach. Take 15-30 min before meals.
Contraindications
Prolactin-releasing pituitary tumour (prolactinoma), conditions where stimulation of gastric motility may be harmful (e.g. gastrointestinal haemorrhage, mechanical obstruction or perforation), known existing prolongation of cardiac conduction intervals (particularly QTc), underlying cardiac disease (e.g. CHF), significant electrolyte disturbances (e.g. hypokalaemia, hypomagnesaemia, hyperkalaemia). Moderate or severe hepatic impairment. Concomitant use with QT-prolonging drugs or potent CYP3A4 inhibitors (e.g. azole antifungals, macrolides, protease inhibitors, nefazodone).
Special Precautions
Patient with personal or family history of breast cancer, risk factors for sudden cardiac arrest (e.g. family history of coronary artery disease, high blood pressure, obesity, hypercholesterolaemia, diabetes, alcoholism, smoking). Renal and mild hepatic impairment. Children and elderly. Pregnancy and lactation.
Storage
Store between 15-30°C. Protect from moisture and light.
MedsGo Class
Antiemetics
Please sign in so that we can notify you about a reply